AlloVir, Inc.

NasdaqCM:ALVR Stock Report

Market Cap: US$49.8m

AlloVir Management

Management criteria checks 2/4

AlloVir's CEO is Vikas Sinha, appointed in Dec 2024, has a tenure of less than a year. total yearly compensation is $2.94M, comprised of 12.7% salary and 87.3% bonuses, including company stock and options. directly owns 0.86% of the company’s shares, worth $426.69K. The average tenure of the management team and the board of directors is 6.1 years and 3.8 years respectively.

Key information

Vikas Sinha

Chief executive officer

US$2.9m

Total compensation

CEO salary percentage12.7%
CEO tenureless than a year
CEO ownership0.9%
Management average tenure6.1yrs
Board average tenure3.8yrs

Recent management updates

Recent updates

AlloVir (NASDAQ:ALVR) Will Have To Spend Its Cash Wisely

Oct 29
AlloVir (NASDAQ:ALVR) Will Have To Spend Its Cash Wisely

Here's Why AlloVir (NASDAQ:ALVR) Must Use Its Cash Wisely

Jul 13
Here's Why AlloVir (NASDAQ:ALVR) Must Use Its Cash Wisely

We Think AlloVir (NASDAQ:ALVR) Needs To Drive Business Growth Carefully

Feb 09
We Think AlloVir (NASDAQ:ALVR) Needs To Drive Business Growth Carefully

Here's Why We're Watching AlloVir's (NASDAQ:ALVR) Cash Burn Situation

Oct 03
Here's Why We're Watching AlloVir's (NASDAQ:ALVR) Cash Burn Situation

Here's Why We're Watching AlloVir's (NASDAQ:ALVR) Cash Burn Situation

Jun 23
Here's Why We're Watching AlloVir's (NASDAQ:ALVR) Cash Burn Situation

Is AlloVir (NASDAQ:ALVR) In A Good Position To Deliver On Growth Plans?

Mar 02
Is AlloVir (NASDAQ:ALVR) In A Good Position To Deliver On Growth Plans?

Is AlloVir (NASDAQ:ALVR) In A Good Position To Deliver On Growth Plans?

Nov 11
Is AlloVir (NASDAQ:ALVR) In A Good Position To Deliver On Growth Plans?

AlloVir GAAP EPS of $0.69 beats by $1.42

Aug 04

AlloVir stock surges on $126.6M securities offering

Jul 27

Is AlloVir (NASDAQ:ALVR) In A Good Position To Invest In Growth?

Jul 27
Is AlloVir (NASDAQ:ALVR) In A Good Position To Invest In Growth?

Here's Why We're Not Too Worried About AlloVir's (NASDAQ:ALVR) Cash Burn Situation

Mar 21
Here's Why We're Not Too Worried About AlloVir's (NASDAQ:ALVR) Cash Burn Situation

AlloVir: A Comparative Study Of Its Manufacturing Process

Feb 07

We're Not Very Worried About AlloVir's (NASDAQ:ALVR) Cash Burn Rate

Nov 02
We're Not Very Worried About AlloVir's (NASDAQ:ALVR) Cash Burn Rate

AlloVir, Inc.: Creating Solutions For Stem Cell Transplant Issues

Oct 02

AlloVir, Inc.'s (NASDAQ:ALVR) Intrinsic Value Is Potentially 24% Below Its Share Price

Aug 06
AlloVir, Inc.'s (NASDAQ:ALVR) Intrinsic Value Is Potentially 24% Below Its Share Price

We Think AlloVir (NASDAQ:ALVR) Can Afford To Drive Business Growth

Jul 01
We Think AlloVir (NASDAQ:ALVR) Can Afford To Drive Business Growth

AlloVir EPS misses by $0.08

May 06

AlloVir (NASDAQ:ALVR) Is In A Good Position To Deliver On Growth Plans

Apr 01
AlloVir (NASDAQ:ALVR) Is In A Good Position To Deliver On Growth Plans

This Insider Has Just Sold Shares In AlloVir, Inc. (NASDAQ:ALVR)

Feb 07
This Insider Has Just Sold Shares In AlloVir, Inc. (NASDAQ:ALVR)

Is AlloVir, Inc.'s (NASDAQ:ALVR) Shareholder Ownership Skewed Towards Insiders?

Jan 08
Is AlloVir, Inc.'s (NASDAQ:ALVR) Shareholder Ownership Skewed Towards Insiders?

FDA clears AlloVir's ALVR106 application in respiratory viruses

Dec 17

Allovir's COVID-19 therapy saw anti-viral activity in pre-clinical data

Dec 07

We Think AlloVir (NASDAQ:ALVR) Can Afford To Drive Business Growth

Dec 04
We Think AlloVir (NASDAQ:ALVR) Can Afford To Drive Business Growth

AlloVir EPS misses by $0.28

Nov 10

CEO Compensation Analysis

How has Vikas Sinha's remuneration changed compared to AlloVir's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$100m

Jun 30 2024n/an/a

-US$140m

Mar 31 2024n/an/a

-US$180m

Dec 31 2023US$3mUS$373k

-US$190m

Sep 30 2023n/an/a

-US$169m

Jun 30 2023n/an/a

-US$167m

Mar 31 2023n/an/a

-US$166m

Dec 31 2022US$3mUS$369k

-US$169m

Sep 30 2022n/an/a

-US$189m

Jun 30 2022n/an/a

-US$192m

Mar 31 2022n/an/a

-US$185m

Dec 31 2021US$7mUS$425k

-US$172m

Sep 30 2021n/an/a

-US$139m

Jun 30 2021n/an/a

-US$117m

Mar 31 2021n/an/a

-US$91m

Dec 31 2020US$6mUS$412k

-US$70m

Sep 30 2020n/an/a

-US$53m

Jun 30 2020n/an/a

-US$37m

Mar 31 2020n/an/a

-US$31m

Dec 31 2019US$2mUS$400k

-US$24m

Compensation vs Market: Vikas's total compensation ($USD2.94M) is above average for companies of similar size in the US market ($USD638.32K).

Compensation vs Earnings: Vikas's compensation has increased whilst the company is unprofitable.

CEO

Vikas Sinha (61 yo)

less than a year

Tenure

US$2,940,669

Compensation

Mr. Vikas Sinha, M.B.A., C.A., CPA, is Director of Orna Therapeutics, Inc. from January 2025. Mr. Sinha is CEO of AlloVir, Inc. from December 19, 2024 and has been its Director since January 2019 and serve...

Leadership Team

NamePositionTenureCompensationOwnership
David Hallal
Executive Chairman of the Board6.4yrsUS$347.00k2.46%
$ 1.2m
Vikas Sinha
CEO & Directorless than a yearUS$2.94m0.86%
$ 426.7k
Edward Miller
General Counsel & Secretary6.1yrsUS$1.89m0.38%
$ 187.8k
Brett Hagen
Chief Accounting Officer6.1yrsno data0.014%
$ 6.9k
Ann Leen
Chief Scientific Officer12.1yrsno datano data

6.1yrs

Average Tenure

58yo

Average Age

Experienced Management: ALVR's management team is seasoned and experienced (6.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
David Hallal
Executive Chairman of the Board6.4yrsUS$347.00k2.46%
$ 1.2m
Vikas Sinha
CEO & Director6.1yrsUS$2.94m0.86%
$ 426.7k
John Mellors
Member of the Scientific Advisory Board2yrsno datano data
Malcolm Brenner
Independent Non-Executive Director13.1yrsUS$196.28k0.20%
$ 99.5k
Jeffrey Bornstein
Independent Non-Executive Director4.6yrsUS$211.78k0.066%
$ 32.7k
Michael Boeckh
Member of Scientific Advisory Board2yrsno datano data
John DiPersio
Member of Scientific Advisory Board2yrsno datano data
Anil Chandraker
Member of Scientific Advisory Board2yrsno datano data
Morana Jovan-Embiricos
Independent Non-Executive Director5.8yrsUS$209.28k8.64%
$ 4.3m
Shawn Tomasello
Independent Director2.9yrsUS$200.73k0.031%
$ 15.2k
Juan Vera
Non-Executive Director11.1yrsUS$187.00k2.08%
$ 1.0m
Gerard Socie
Member of Scientific Advisory Board2yrsno datano data

3.8yrs

Average Tenure

59.5yo

Average Age

Experienced Board: ALVR's board of directors are considered experienced (3.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/07 19:59
End of Day Share Price 2025/02/07 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

AlloVir, Inc. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason ZemanskyBofA Global Research
Anupam RamaJ.P. Morgan
Christopher RaymondPiper Sandler Companies